載入...
Reappraising antiangiogenic therapy for breast cancer
Phase III trials of antiangiogenic drugs for metastatic breast cancer have either had only limited success, e.g. the monoclonal anti-VEGF antibody bevacizumab when used with various conventional chemotherapy regimens, or have failed altogether, e.g. the small molecule oral tyrosine kinase inhibitor...
Na minha lista:
| 發表在: | Breast |
|---|---|
| 主要作者: | |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2011
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4540338/ https://ncbi.nlm.nih.gov/pubmed/22015294 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0960-9776(11)70295-8 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|